Disruption of constitutive CXCR4 oligomers impairs oncogenic properties in lymphoid neoplasms.

Saved in:
Bibliographic Details
Title: Disruption of constitutive CXCR4 oligomers impairs oncogenic properties in lymphoid neoplasms.
Authors: Mobach S; Department of Chemistry and Pharmaceutical Sciences, Division of Medicinal Chemistry, Amsterdam Institute for Molecular and Life Sciences, Vrije Universiteit Amsterdam, Amsterdam 1081 HZ, The Netherlands.; Amsterdam University Medical Center location University of Amsterdam, Department of Hematology, Amsterdam 1105 AZ, The Netherlands.; Lymphoma and Myeloma Center Amsterdam, Amsterdam 1105 AZ, The Netherlands., Bergkamp ND; Department of Chemistry and Pharmaceutical Sciences, Division of Medicinal Chemistry, Amsterdam Institute for Molecular and Life Sciences, Vrije Universiteit Amsterdam, Amsterdam 1081 HZ, The Netherlands., Ma Z; Department of Biomolecular Mass Spectrometry and Proteomics, Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht 3584 CH, The Netherlands.; Singapore Immunology Network, Agency for Science, Technology and Research, Immunos, Singapore 138648, Republic of Singapore., Haselager MV; Amsterdam University Medical Center location University of Amsterdam, Department of Hematology, Amsterdam 1105 AZ, The Netherlands.; Lymphoma and Myeloma Center Amsterdam, Amsterdam 1105 AZ, The Netherlands.; Cancer Center Amsterdam, Cancer Immunology, Amsterdam 1081 HV, The Netherlands., Anbuhl SM; Department of Chemistry and Pharmaceutical Sciences, Division of Medicinal Chemistry, Amsterdam Institute for Molecular and Life Sciences, Vrije Universiteit Amsterdam, Amsterdam 1081 HZ, The Netherlands.; QVQ Holding B.V., Utrecht 3584 CL, The Netherlands., Jurriens D; Cell Biology, Neurobiology and Biophysics, Department of Biology, Faculty of Science, Utrecht University, Utrecht 3584 CH, Netherlands., van den Bor J; Department of Chemistry and Pharmaceutical Sciences, Division of Medicinal Chemistry, Amsterdam Institute for Molecular and Life Sciences, Vrije Universiteit Amsterdam, Amsterdam 1081 HZ, The Netherlands., Wang Z; Receptor Signaling Group, Max Delbrück Center for Molecular Medicine, Berlin 13125, Germany.; ISAR Bioscience Institute, Planegg 82152, Germany., Crudden C; Department of Chemistry and Pharmaceutical Sciences, Division of Medicinal Chemistry, Amsterdam Institute for Molecular and Life Sciences, Vrije Universiteit Amsterdam, Amsterdam 1081 HZ, The Netherlands., Roos JL; Amsterdam University Medical Center location University of Amsterdam, Department of Hematology, Amsterdam 1105 AZ, The Netherlands.; Lymphoma and Myeloma Center Amsterdam, Amsterdam 1105 AZ, The Netherlands.; Cancer Center Amsterdam, Cancer Immunology, Amsterdam 1081 HV, The Netherlands., Perez Almeria CV; Department of Chemistry and Pharmaceutical Sciences, Division of Medicinal Chemistry, Amsterdam Institute for Molecular and Life Sciences, Vrije Universiteit Amsterdam, Amsterdam 1081 HZ, The Netherlands., Boergonje RA; Department of Chemistry and Pharmaceutical Sciences, Division of Medicinal Chemistry, Amsterdam Institute for Molecular and Life Sciences, Vrije Universiteit Amsterdam, Amsterdam 1081 HZ, The Netherlands., Lohse MJ; Receptor Signaling Group, Max Delbrück Center for Molecular Medicine, Berlin 13125, Germany.; ISAR Bioscience Institute, Planegg 82152, Germany., Bosma R; Department of Chemistry and Pharmaceutical Sciences, Division of Medicinal Chemistry, Amsterdam Institute for Molecular and Life Sciences, Vrije Universiteit Amsterdam, Amsterdam 1081 HZ, The Netherlands., Eldering E; Lymphoma and Myeloma Center Amsterdam, Amsterdam 1105 AZ, The Netherlands.; Cancer Center Amsterdam, Cancer Immunology, Amsterdam 1081 HV, The Netherlands.; Amsterdam University Medical Center location University of Amsterdam, Department of Experimental Immunology, Amsterdam 1105 AZ, The Netherlands.; Amsterdam Institute for Infection and Immunity, Cancer Immunology, Amsterdam 1105 AZ, The Netherlands., Siderius M; Department of Chemistry and Pharmaceutical Sciences, Division of Medicinal Chemistry, Amsterdam Institute for Molecular and Life Sciences, Vrije Universiteit Amsterdam, Amsterdam 1081 HZ, The Netherlands., Wu W; Department of Biomolecular Mass Spectrometry and Proteomics, Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht 3584 CH, The Netherlands.; Singapore Immunology Network, Agency for Science, Technology and Research, Immunos, Singapore 138648, Republic of Singapore.; Department of Pharmacy and Pharmaceutical Sciences, Faculty of Science, National University of Singapore, Singapore 117543, Republic of Singapore., Spaargaren M; Lymphoma and Myeloma Center Amsterdam, Amsterdam 1105 AZ, The Netherlands.; Department of Pathology, Amsterdam University Medical Center location University of Amsterdam, Amsterdam 1105 AZ, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology-Target & Therapy discovery, Amsterdam 1081 HV, The Netherlands., Tonino SH; Amsterdam University Medical Center location University of Amsterdam, Department of Hematology, Amsterdam 1105 AZ, The Netherlands.; Lymphoma and Myeloma Center Amsterdam, Amsterdam 1105 AZ, The Netherlands., Kater AP; Amsterdam University Medical Center location University of Amsterdam, Department of Hematology, Amsterdam 1105 AZ, The Netherlands.; Lymphoma and Myeloma Center Amsterdam, Amsterdam 1105 AZ, The Netherlands., Smit MJ; Department of Chemistry and Pharmaceutical Sciences, Division of Medicinal Chemistry, Amsterdam Institute for Molecular and Life Sciences, Vrije Universiteit Amsterdam, Amsterdam 1081 HZ, The Netherlands., Heukers R; Department of Chemistry and Pharmaceutical Sciences, Division of Medicinal Chemistry, Amsterdam Institute for Molecular and Life Sciences, Vrije Universiteit Amsterdam, Amsterdam 1081 HZ, The Netherlands.; QVQ Holding B.V., Utrecht 3584 CL, The Netherlands.
Source: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2025 Jun 17; Vol. 122 (24), pp. e2424186122. Date of Electronic Publication: 2025 Jun 11.
Publication Type: Journal Article
Journal Info: Publisher: National Academy of Sciences Country of Publication: United States NLM ID: 7505876 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1091-6490 (Electronic) Linking ISSN: 00278424 NLM ISO Abbreviation: Proc Natl Acad Sci U S A Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1091-6490
DOI:10.1073/pnas.2424186122